title: [Clinical evaluation of cefpirome sulfate for severe infections in patients with hematological disorders. Hanshin Study Group of Hematopoietic Disorders and Infections].
abstract: We investigated the therapeutic efficacy and safety of cefpirome sulfate (CPR) in treatment of hematopoietic disorder-associated infections. A total of 219 patients were admitted to 12 hospitals of Hanshin Study Group of hematopoietic disorders and infections between April 1994 and March 1996 and were enrolled in this study. Most patients received intravenously infused CPR at a dose of 1 or 2 g twice a day for 3 days or more. Twenty nine patients dropped out or were excluded and remaining 190 patients were adopted for the evaluation. A overall response rate was 58.4% (111/190). Among neutropenic patients, the response rate was 50% (8/16) in patients whose peripheral neutrophil counts (PNC) remained less than 100/microliter throughout the observation period and was 53.7% (22/41) in patients with PNC remained less than 500/microliter. In contrast, in patient whose PNC was below 500 before the treatment but exceeded 501/microliter during of at the end of the treatment, the response rate was as high as 78.4% (29/37). When G-CSF was combined, the response rate became significantly (P < 0.05) higher, 68.5% (50/73), as compared with that, 52.1% (61/117), in patients without it. In cases in which the causative organisms could be identified, the organisms were eliminated in 81.8% (9/11) of the patients infected with Gram-positive bacteria, whereas in 100% (12/12) in those infected with Gram-negative bacteria. Skin eruption developed in 6 patients during the treatment with CPR, and vascular pain and parosmia in one each other. These symptoms subsided soon after discontinuation or even without discontinuation of CPR. Abnormal laboratory findings, mainly liver dysfunction, i.e. elevation of slight degree of serum transaminase levels, were observed. The values, however, turned to normal immediately after the cessation or completion of the treatment. In conclusion, CPR is considered to be an antibiotic of value with high efficacy and safety in treatment of hematopoietic disorder-associated infections.
authors.affiliation: Third Department of Internal Medicine, Kinki University School of Medicine.
authors.forename: H
authors.initials: H
authors.lastname: Hamazaki
authors.forename: H
authors.initials: H
authors.lastname: Hasegawa
authors.forename: A
authors.initials: A
authors.lastname: Horiuchi
authors.forename: H
authors.initials: H
authors.lastname: Teshima
authors.forename: A
authors.initials: A
authors.lastname: Hiraoka
authors.forename: T
authors.initials: T
authors.lastname: Masaoka
authors.forename: K
authors.initials: K
authors.lastname: Nasu
authors.forename: H
authors.initials: H
authors.lastname: Uchino
authors.forename: N
authors.initials: N
authors.lastname: Tatsumi
authors.forename: N
authors.initials: N
authors.lastname: Inoue
authors.forename: T
authors.initials: T
authors.lastname: Kageyama
authors.forename: H
authors.initials: H
authors.lastname: Kawagoe
authors.forename: M
authors.initials: M
authors.lastname: Tukaguchi
authors.forename: S
authors.initials: S
authors.lastname: Hukuhara
authors.forename: T
authors.initials: T
authors.lastname: Takahashi
authors.forename: H
authors.initials: H
authors.lastname: Takatsuka
authors.forename: A
authors.initials: A
authors.lastname: Kanamaru
authors.forename: E
authors.initials: E
authors.lastname: Kakishita
authors.forename: K
authors.initials: K
authors.lastname: Nagai
authors.forename: H
authors.initials: H
authors.lastname: Hara
authors.forename: Y
authors.initials: Y
authors.lastname: Kanayama
authors.forename: H
authors.initials: H
authors.lastname: Sugiyama
authors.forename: T
authors.initials: T
authors.lastname: Kitani
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy*; D002511:Cephalosporins / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006402:Hematologic Diseases / Q000150:complications*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000150:complications / Q000188:drug therapy*; D000097572:Cefpirome
chemical_list: D002511:Cephalosporins; D016179:Granulocyte Colony-Stimulating Factor; D000097572:Cefpirome